Key Points Question What are the efficacy and safety of bicistronic CD19/CD22 chimeric antigen receptor (CAR) T-cell therapy in children with relapsed or refractory acute lymphoblastic leukemia? Findings In this phase 2 nonrandomized clinical trial, bicistronic CD19/CD22 CAR T-cell therapy induced minimal residual disease–negative remission in most patients and was associated with favorable event-free survival in hematologic and isolated extramedullary relapse.
Xiaoxi Lu
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Xiaoxi
Contact Xiaoxi, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack